These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31884564)

  • 1. 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.
    Craven ER; Walters T; Christie WC; Day DG; Lewis RA; Goodkin ML; Chen M; Wangsadipura V; Robinson MR; Bejanian M;
    Drugs; 2020 Feb; 80(2):167-179. PubMed ID: 31884564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.
    Lewis RA; Christie WC; Day DG; Craven ER; Walters T; Bejanian M; Lee SS; Goodkin ML; Zhang J; Whitcup SM; Robinson MR;
    Am J Ophthalmol; 2017 Mar; 175():137-147. PubMed ID: 28012819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
    Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
    Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure.
    Lee SS; Dibas M; Almazan A; Robinson MR
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):138-144. PubMed ID: 30698494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.
    Seal JR; Robinson MR; Burke J; Bejanian M; Coote M; Attar M
    J Ocul Pharmacol Ther; 2019; 35(1):50-57. PubMed ID: 30335560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study.
    Choi EY; Johnson NA; Stinnett S; Rosdahl J; Moya F; Herndon LW
    J Glaucoma; 2024 Jun; 33(6):431-436. PubMed ID: 38506759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
    Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
    PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension.
    Medeiros FA; Sheybani A; Shah MM; Rivas M; Bai Z; Werts E; Ahmed IIK; Craven ER
    Ophthalmol Ther; 2022 Aug; 11(4):1517-1537. PubMed ID: 35643967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
    Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
    BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
    Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
    Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes.
    Weinreb RN; Christie WC; Medeiros FA; Craven ER; Kim K; Nguyen A; Bejanian M; Wirta DL
    Ophthalmol Glaucoma; 2023; 6(6):599-608. PubMed ID: 37343625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.
    Lee SS; Burke J; Shen J; Almazan A; Orilla W; Hughes P; Zhang J; Li H; Struble C; Miller PE; Robinson MR
    Vet Ophthalmol; 2018 Jul; 21(4):376-381. PubMed ID: 29457333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
    Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
    Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States.
    Teymoorian S; Craven ER; Nguyen L; Werts E
    Clin Ophthalmol; 2024; 18():187-199. PubMed ID: 38263954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma.
    Wong MK; Bowers ME; Ventimiglia J; Niknam RM; Moster MR; Pro MJ; Dale E; Kolomeyer NN; Lee D; Zheng CX
    J Glaucoma; 2023 Sep; 32(9):738-743. PubMed ID: 37523637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.